When it comes to identifying cancer, there's no such thing as too early. GlycoKnow™ Colon will be available in 2023 as a laboratory-developed risk assessment test that uses glycopeptide and peptide biomarkers to assess the risk of pre-cancerous polyps and colorectal cancer. Now, a single blood draw will be able to put patients with an increased risk of colon cancer on the path to receiving care before a tumor has developed.
GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing methods.
Single-tube blood draw
True pre-cancer detection with unmatched advanced adenoma sensitivity
Rapid 10-day
turnaround time
InterVenn’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our tests are developed, and the performance characteristics are determined by InterVenn. Our tests have not been cleared or approved by the U.S. Food and Drug Administration. InterVenn’s clinical laboratory is regulated under CLIA to perform high-complexity testing. Our tests are not intended for clinical purposes.
| Indication | Clinical Application | Phase | |||||
|---|---|---|---|---|---|---|---|
| Proof of Concept | Classifier Validation | LDT Validation | Commercially Available | ||||
| GLORI™ | Pelvic Mass Triaging | ||||||
| DAWN™ IO Melanoma | Immuno-Therapy Response Prediction | ||||||
| Non-Small Cell Lung Carcinoma (NSCLC) | Immuno-Therapy Response Prediction | ||||||
| GlycoKnow™ Colon | Pre-Malignant Detection, Cancer Prevention | Expected Launch in 2023 | |||||
| Multiple Cancer Early Detection: Breast, Colon, Lung, Pancreas, Prostate | Early Detection | ||||||
| Treatment Monitoring Panel: Autoimmune | Disease Monitoring | ||||||
| Treatment Monitoring Panel: Inflammation | Disease Monitoring | ||||||
| Treatment Monitoring Panel: Infectious Disease | Disease Monitoring | ||||||
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
